LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.91 -2.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.88

Max

3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 49.052
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+312.75% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-270M 640M
Ankstesnė atidarymo kaina	5.26
Ankstesnė uždarymo kaina	2.91

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-10 23:36; UTC

Uždarbis

Correction to Oracle Reports Higher 4Q Profit Article

2026-06-10 23:19; UTC

Karštos akcijos

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026-06-10 23:09; UTC

Pagrindinės rinkos jėgos

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026-06-10 23:04; UTC

Uždarbis

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026-06-10 20:44; UTC

Pagrindinės rinkos jėgos

Caterpillar Raises Quarterly Dividend 8%

2026-06-10 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Should Take No Options Off The Table

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026-06-10 23:47; UTC

Rinkos pokalbiai

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026-06-10 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026-06-10 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026-06-10 23:32; UTC

Rinkos pokalbiai

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026-06-10 23:20; UTC

Rinkos pokalbiai

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026-06-10 22:05; UTC

Rinkos pokalbiai

Correction to Bank of Canada Stays on Hold Market Talk

2026-06-10 21:57; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:52; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:35; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:22; UTC

Uždarbis

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026-06-10 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-10 20:39; UTC

Rinkos pokalbiai

Uždarbis

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026-06-10 20:34; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 20:33; UTC

Uždarbis

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

312.75% į viršų

12 mėnesių prognozė

Vidutinis 12.3 USD 312.75%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

10

Pirkti

0

Laikyti

0

Parduoti

Remiantis 10 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Kitos sektoriaus akcijos

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat